These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2145440)

  • 21. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children.
    McDonald LR; McCarthy CH
    Clin J Oncol Nurs; 2006 Dec; 10(6):809-15. PubMed ID: 17193947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
    J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
    Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
    Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of dexamethasone before remission induction, in de novo childhood acute lymphoblastic leukemia.
    López-Hernández MA; Alvarado M; De Diego J; Borbolla-Escoboza JR; Jiménez RM; Trueba E
    Haematologica; 2004 Mar; 89(3):365-6. PubMed ID: 15020281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Ochs J; Rodman J; Abromowitch M; Kavanagh R; Harris M; Yalowich J; Rivera GK
    J Clin Oncol; 1991 Jan; 9(1):139-44. PubMed ID: 1985163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of monoclonal antibodies in acute lymphoblastic leukemia in children. II. Clinical picture and prognosis in specific immunological subgroups].
    Kołecki P; Radwańska U
    Pediatr Pol; 1988 Nov; 63(11):698-702. PubMed ID: 3253656
    [No Abstract]   [Full Text] [Related]  

  • 31. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
    Yetgin S; Tuncer MA; Cetin M; Gümrük F; Yenicesu I; Tunç B; Oner AF; Toksoy H; Koç A; Aslan D; Ozyürek E; Olcay L; Atahan L; Tunçbilek E; Gürgey A
    Leukemia; 2003 Feb; 17(2):328-33. PubMed ID: 12592331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recurrences after completion of the treatment of acute lymphoblastic leukemia in children].
    Ochocka M; Matysiak M; Newecka-Samól T; Kulus M; Armata J; Balwierz W; Bogusławska-Jaworska J; Chybicka A; Jackowska T; Jakowicka M
    Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):350-3. PubMed ID: 1437752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Rheingold SR; Tasian SK; Whitlock JA; Teachey DT; Borowitz MJ; Liu X; Minard CG; Fox E; Weigel BJ; Blaney SM
    Br J Haematol; 2017 May; 177(3):467-474. PubMed ID: 28295182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
    Nakadate H; Hatayama Y; Hatae Y; Takeda T
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2907-10. PubMed ID: 3178240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL
    J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Report on induction efficacy of protocol ALL-2005 and middle term follow-up of 158 cases of childhood acute lymphoblastic leukemia].
    Tang JY; Gu LJ; Xue HL; Chen J; Pan C; Wu WT; Shen SH; Dong L; Zhou M; Ye QD; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):289-93. PubMed ID: 19799121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.